Riet Tobias, Abken Hinrich
Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Expert Rev Hematol. 2015 Aug;8(4):383-5. doi: 10.1586/17474086.2015.1043884. Epub 2015 May 6.
Adoptive cell therapy for malignant diseases is showing promise in recent early-phase trials in the treatment of B cell leukemia/lymphoma. Genetically engineered with a tumor-specific chimeric antigen receptor, patient's T cells produce lasting and complete leukemia regression. However, treatment is associated with some toxicity which needs our attention and the field still faces some hurdles at the scientific, technologic and clinical levels. Surmounting these obstacles will establish chimeric antigen receptor T cell therapy as a powerful approach to cure hematologic malignancies, paving the way for the treatment of other common types of cancer in the future.
过继性细胞疗法在近期治疗B细胞白血病/淋巴瘤的早期试验中显示出前景。通过基因工程改造使其带有肿瘤特异性嵌合抗原受体，患者的T细胞可使白血病实现持久且完全的消退。然而，该治疗伴有一些毒性，需要我们关注，并且该领域在科学、技术和临床层面仍面临一些障碍。克服这些障碍将使嵌合抗原受体T细胞疗法成为治愈血液系统恶性肿瘤的有力方法，为未来治疗其他常见癌症类型铺平道路。
